Lynx1 Capital Management as of March 31, 2025
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 14 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gh Research Ordinary Shares (GHRS) | 25.5 | $71M | 6.4M | 11.03 | |
| Merus N V (MRUS) | 23.6 | $66M | 1.6M | 42.09 | |
| Protagonist Therapeutics (PTGX) | 12.7 | $35M | 733k | 48.36 | |
| Stoke Therapeutics (STOK) | 12.6 | $35M | 5.3M | 6.65 | |
| Cullinan Oncology (CGEM) | 8.7 | $24M | 3.2M | 7.57 | |
| Allogene Therapeutics (ALLO) | 5.8 | $16M | 11M | 1.46 | |
| C4 Therapeutics Com Stk (CCCC) | 4.1 | $11M | 7.1M | 1.60 | |
| Tscan Therapeutics (TCRX) | 2.6 | $7.4M | 5.4M | 1.38 | |
| Precision Biosciences Com New (DTIL) | 1.3 | $3.7M | 766k | 4.77 | |
| Ibio Con New (IBIO) | 1.2 | $3.5M | 862k | 4.02 | |
| Passage Bio | 1.2 | $3.3M | 9.3M | 0.35 | |
| Upstream Bio (UPB) | 0.5 | $1.3M | 219k | 6.12 | |
| Neuphoria Therapeutics (NEUP) | 0.1 | $264k | 46k | 5.76 | |
| Design Therapeutics (DSGN) | 0.1 | $255k | 66k | 3.86 |
